Perspective Therapeutics, Inc. annual report, FY2021

Filing identity and reporting period

The supplied document is Isoray, Inc.’s Form 10-K for the fiscal year ended June 30, 2021—not a Perspective Therapeutics filing or a 2020 Q4 report. It includes unaudited quarterly results through the quarter ended June 30, 2021. Isoray traded as ISR on NYSE American.

Business context

Isoray develops, manufactures, and sells Cesium-131 brachytherapy seeds and delivery formats for cancer treatment. Prostate cancer remained its largest market; other applications included brain, lung, gynecological, and head-and-neck cancers. Fiscal 2021 sales were overwhelmingly domestic.

Financial results and liquidity

Operating expenses totaled $8.567 million, down slightly from $8.600 million. The company reported $3.010 million in total liabilities, including lease liabilities and an asset-retirement obligation; the filing does not report borrowings or other financial debt. Net cash increased $61.437 million, primarily because of financing proceeds. The company raised $56.375 million net from underwritten stock offerings and received $7.784 million from warrant exercises and $0.534 million from option exercises. Shares outstanding rose from 68.9 million at June 30, 2020 to 141.9 million at June 30, 2021.

Material changes versus the prior year

• Sales increased 4%. Other cancer-related sales rose 68% to $2.229 million, while prostate sales fell 6% to $7.824 million. Prostate represented 78% of FY2021 sales versus 86% in FY2020.
• Gross profit was nearly unchanged despite higher sales; gross margin declined about 2 percentage points, reflecting higher labor and material costs, freight expense, and unused isotope inventory.
• Net loss narrowed modestly, and cash used in operations declined. The large increase in cash and working capital followed substantial equity financing, rather than operating cash generation.
• GT Medical Technologies accounted for 11.3% of FY2021 revenue, compared with less than 10% in FY2020; the filing also reports significant revenue concentration among a physician practice/facilities and other major customers.

Outlook, risks, and unusual items

Management forecast a 25% revenue increase for FY2022 and estimated cash-flow break-even in three to four years if growth targets are met and no extraordinary expenses arise. These are targets, not assurances. The company expects increased isotope-related costs during the first half of FY2022 as it works to establish a second supply route.

• Supply concentration: Cesium-131 supply depended on Russian sources, and reactor outages, shipping disruptions, sanctions, or supplier problems could affect production. A September 2021 arrangement involving enriched barium and third parties was intended to mitigate supply risk, but execution and volumes were not assured.
• COVID-19 and demand: Pandemic-related restrictions and hospital capacity pressures delayed or canceled procedures and constrained customer access; future effects, including variants, were uncertain.
• Market and reimbursement: Prostate brachytherapy faces competition from external-beam radiation, surgery, and other treatments. Reimbursement levels and adoption of newer non-prostate applications remain uncertain. CMS had proposed removing brachytherapy from the Radiation Oncology Model; management was evaluating the potential impact.
• Execution and concentration: The business relies on one product, a concentrated customer base, clinical acceptance, and successful commercialization by partners, including GT Medical. GammaTile-related sales growth was not assured.
• Other disclosures: The filing reports no legal proceedings and no off-balance-sheet arrangements. The company remained loss-making, with an accumulated deficit of $91.325 million. The independent auditor issued an unqualified opinion and reported no critical audit matters; management stated internal controls were effective.

Key facts for investors to verify

1. Confirm the issuer and period: this is Isoray’s FY2021 10-K, not a Perspective Therapeutics filing or FY2020 Q4 filing.
2. Review the FY2022 revenue-growth target and assumptions underlying management’s three-to-four-year cash-flow break-even estimate.
3. Track whether the alternative Russian isotope supply arrangement is completed, delivers expected quantities, and controls costs.
4. Assess customer concentration, GT Medical’s sales performance, and the sustainability of growth in non-prostate applications.
5. Monitor gross-margin trends, ongoing operating cash burn, future financing needs, and dilution following the FY2021 equity offerings.
6. Check final CMS reimbursement rules and whether treatment volumes recover from pandemic-related disruption.